Premium
A CONTINUOUS INDIVIDUALIZED RISK INDEX FOR REFINED OUTCOME PREDICTION AFTER TARGETED THERAPY FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CIRI‐CLL)
Author(s) -
AlSawaf O.,
Esfahani M. S.,
Zhang C.,
Tausch E.,
Schilhabel A.,
Eichhorst B.,
Stilgenbauer S.,
Hallek M.,
Alizadeh A. A.,
Kurtz D. M.,
Fischer K.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.51_2880
Subject(s) - venetoclax , chemoimmunotherapy , context (archaeology) , medicine , chronic lymphocytic leukemia , oncology , ighv@ , hazard ratio , leukemia , confidence interval , paleontology , biology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom